NICE outlines process for developing biosimilars guidance

The U.K.'s NICE released a position statement reviewing its process for developing guidance on biosimilars.

NICE said most biosimilars will be reviewed under a Multiple Technology Appraisal ( MTA) in parallel with the reference product. The appraisals will use the name of the active drug substance and will include brand names only where it is appropriate to inform clinical decision making. ...